Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction

Zeitschrift fur Kardiologie

Volumn 94, Issue 5, 2005, Pages 328-335

  Fassbach, M ^a   Schwartzkopff, B ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Collagen; Diastolic dysfunction; Hypertrophic cardiomyopathy; Matrix metalloproteinase; PICP

Indexed keywords

COLLAGEN TYPE 1; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BIOACCUMULATION; CLINICAL ARTICLE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; PROTEIN DEGRADATION;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; COLLAGEN TYPE I; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART SEPTUM; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; MYOCARDIAL CONTRACTION; REFERENCE VALUES; STATISTICS; STROKE VOLUME; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR DYSFUNCTION, LEFT;

EID: 18844414847     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-005-0214-5     Document Type: Article

References (36)

1. Beer G, Reinecke P, Gabbert HE et al (2002) Fabry disease in patients with hypertrophic cardiomyopathy (HCM). Z Kardiol 91(12):992-1002
2. Briguori C, Betocchi S, Romano M et al (1999) Exercise capacity in hypertrophic cardiomyopahty depends on left ventricular diastolic function. Am J Cardiol 84:309-315
3. Brilla CG, Maisch B, Zhou G et al (1995) Hormonal regulation of cardiac fibroblast function. Eur Heart J 16 (Suppl C):45-50
4. Burlew BS, Weber KT (2002) Cardiac fibrosis as a cause of diastolic dysfunction. Herz 27(2):92-98
5. Cecchi F, Olivotto I, Gistri R et al (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349(11):1027-1135
6. Chikamori T, Counihan PJ, Doi YL et al (1992) Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol 19:507-512
7. Diez J, Laviades C, Monreal I et al (1995) Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Am J Cardiol 76(13):14D-17D
8. Dohlemann C, Hebe J, Meitinger T (2000) Apical hypertrophic cardiomyopathy due to a de novo mutation Arg719Trp of the b-myosin heavy chain gene and cardiac arrest in childhood: A case report and family study. Z Kardiol 89(7):612-619
9. Eriksen EF, Charles P, Melsen F et al (1993) Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation to bone histomorphometry. J Bone Miner Res 8:127-132
10. Factor SM, Butany J, Sole MJ, Wigle ED et al (1982) Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 17:1343-1351
11. Johnson RA, Palacios I (1982) Dilated cardiomyopathies of the adult. N Engl J Med 307:1051-1058
12. Kuhn H, Gietzen FH, Leuner C (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89 (Suppl 4):IV41-54
13. Laviades C, Varo N, Fernandez J et al (1998) Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circ 98(6):535-540
14. Lawrenz T, Kuhn H (2004) Endocardial radiofrequency ablation of septal hypertrophy: A new catheter based modality of gradient reduction in hypertrophic obstructive cardiomyopathy. Z Kardiol 93(6):493-499
15. Lombardi R, Betocchi S, Losi MA et al (2003) Myocardial collagen turnover in hypertrophic cardiomyopathy. Circ 108(12):1466-1460
16. Maron BJ, Gardin JM, Flack JM et al (1995) Prevalence of hypertrophic cardiomypoathy in a general population of young adults. Circulation 92:785-789
17. Maron BJ, Gottiener JS, Epstein SE (1981) Patterns and significance of distribution of left ventricular hypertrophy in hypertophic cardiomyopathy. Am J Cardiol 48:418-428
18. Maron BJ, Wolfson JK, Epstein SE et al (1986) Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 8:545-557
19. Maron BJ, Wolfson JK, Epstein SE et al (1987) Morphologic evidence for small vessel disease in patients with hypertrophic cardiomyopathy. Z Kardiol 76(Suppl 3):91-100
20. Moon JCC, McKenna WJ, McCrohon JA et al (2003) Toward Clinical Risk Assessment in Hypertrophic Cardiomyopathy With Gadolinium Cardiovascular Magnetic Resonance. J Am Coll Cardiol 41:1561-1567
21. Mundhenke M, Stark P, Schulte HD et al (2002) Myocardial collagen type I and impaired left ventricular function under exercise in hypertrophic cardiomyopathy. Thorac Cardiovasc Surg 50(4):216-222
22. Nishimura RA, Tajik AJ (1997) Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 30(1):1-18
23. Sahn DJ, DeMaria A, Kisslo J et al (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circ 58:1072-1083
24. Schwammenthal E, Block M, Schwartzkopff B et al (1992) Prediction of the site and severity of obstruction in hypertrophic cardiomyopathy by color flow mapping and continuous wave Doppler echocardiography. J Am Coll Cardiol 20(4):964-972
25. Schwartzkopff B, Fassbach M, Pelzer B et al (2002) Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4:439-444
26. Schwartzkopff B, Mundhenke M, Strauer BE (1998) Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. J Am Coll Cardiol 31 (5):1089-1096
27. Shirani J, Pick R, Roberts WC et al (2000) Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 35(1):36-44
28. Spinale FG, Coker ML, Krombach SR et al (1999) Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85(4):364-376
29. Stetler-Stevenson WG (1996) Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 148:1345-1350
30. Strauer BE, Atef Mahmoud M, Bayer F et al (1984) Reversal of left ventricular hypertrophy and improvement of cardiac function in man by nifedipine. Eur Heart J 5(Suppl F):53-60
31. Sys SU, Brutsaert DL (1995) Diagnostic Significance of Impaired LV Systolic Relaxation in Heart Failure. Circulation 92:3377-3380
32. Tanaka M, Fujiwara H, Onodera T et al (1986) Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts and hypertrophic cardiomyopathy. Br Heart J 55:575-581
33. Tyagi SC, Campbell SE, Reddy HK et al (1996) Matrix metalloproteinase activity expression in infarcted, non-infarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 155:13-21
34. Tyagi SC, Kumar SG, Banks J et al (1995) Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol 27(10):2177-2189
35. Wigle ED, Rakowski H, Kimball BP et al (1995) Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 92:1680-1692
36. Zu Vilsendorf DM, Strunk-Mueller C, Gietzen FH, Kuhn H (2002) Simultaneous hypertrophic obstructive cardiomyopathy and long QT syndrome: a potentially malignant association. Z Kardiol 91(7):575-580